Forkhead box M1 (FoxM1), a transcription factor of the Forkhead family, is demonstrated to be critical for proliferation, apoptosis, migration and invasion of lung cancer. In this study, we extensively investigated the anticancer effect of siomycin A, which was identified as an inhibitor of FoxM1 transcriptional activity, on human lung adenocarcinoma A549 cells. Our study indicated that treatment with siomycin A resulted in the suppression of FoxM1 expression, which consequently contributed to its effect of cell growth inhibition and cell apoptosis induction in A549 cells. Then the molecular mechanism of siomycin A's apoptotic action on A549 cells was further investigated. The results revealed that siomycin A induced apoptosis by influencing the downstream events of FoxM1, including inhibiting the expression of Bcl-2 and Mcl-1, as well as leading to caspase-3 cleavage. Taken together, our findings may be useful for understanding the mechanism of action of siomycin A on lung cancer cells and provide new insights into the possible application of such a compound in lung cancer therapy in the future.
Lung cancer is the most common malignant tumor worldwide, and is one of the leading causes of human cancer-related deaths [1, 2] . Human lung cancers are classified into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) . Approximately 70%-80% of lung cancers are NSCLC, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma [3, 4] . Currently, lung cancer is mainly treated by either surgery or radiation therapy followed by chemotherapy [5] . Some chemical agents have been applied to treat such cancer, but the outcome was unsatisfactory primarily due to the development of drug resistance and the adverse effects of the anti-tumor drugs [6] . Therefore, the search for novel anti-tumor agents that circumvent these limitations has proved to be urgent.
Forkhead box M1 (FoxM1) is a transcription factor of the Forkhead family, which consists of more than 50 transcription factors [7] . FoxM1 is overexpressed in a variety of human solid tumors. In particular, elevated FoxM1 levels were abundantly expressed in highly proliferative human lung cancers [8] [9] [10] [11] . A previous study demonstrated that deletion of mouse FoxM1 caused a significant reduction in the proliferation of lung tumor cells, as well as in the number and size of lung adenomas following urethane lung tumor induction [12, 13] . These suggested that an alternative approach to chemotherapy of lung cancer would be to inhibit FoxM1, a master regulator of cell growth.
Siomycin A, known as a thiazole antibiotic, was previously identified as an inhibitor of FoxM1 [14] . In this study, the anticancer A B Figure 1 : Siomycin A suppresses FoxM1 expression in human lung adenocarcinoma A549 cells. Cells were treated with siomycin A (0, 2.5, 5, 10 μM) for 24 h and then the relative mRNA and protein expression of FoxM1 was assessed by RT-PCR (A) and Western blot analysis (B). The results are shown as mean±SD of three independent experiments (n=3) and each experiment included triplicate sets. *p<0.05, **p<0.01 vs. control. effect of siomycin A on human lung adenocarcinoma A549 cells was investigated for the first time. The underlying molecular mechanism of such an effect was also explored in regards to cell proliferation, cell apoptosis and the expression of apoptosis-related molecules on A549 cells treated with siomycin A.
FoxM1 expression is suppressed by siomycin A:
Human lung adenocarcinoma A549 cells were reported to express high levels of FoxM1 [15] . However, the influence of siomycin A on FoxM1 expression in A549 cells was never investigated. As shown in Figure 1 , siomycin A significantly suppressed the expression of FoxM1 both in mRNA and protein levels in A549 cells in a dosedependent manner. These data indicated that siomycin A could suppress FoxM1 expression in A549 cells, which might consequently induce cell damage.
Effect of siomycin A on cell proliferation:
Because FoxM1 could stimulate the proliferation of lung cancer cells, then whether suppression of FoxM1 by siomycin A could inhibit cell growth in A549 cells was evaluated by MTT assay. As shown in Figure 2 , treatment with siomycin A remarkably induced proliferation inhibition in A549 cells. The inhibition of cell growth was dosedependent, with an IC 50 value at 24 h of 2.12 μM. Our results indicated that siomycin A had an inhibitory effect on lung adenocarcinoma A549 cells which might be through inhibiting FoxM1. 
Effect of siomycin A on cell apoptosis:
The effect of siomycin A on cell apoptosis was assessed by flow cytometric analysis. The results indicated that the percentage of apoptotic cells was significantly increased by treatment with siomycin A at 2.5 μM (24.3%±2.2%), 5 μM (36.3%±4.6%) and 10 μM (42.6%±5.7%) for 24 h in comparison with the control (1.7%±0.6%) (p<0.05). Our data suggested that siomycin A could inhibit the growth of A549 cells by inducing apoptosis.
Effect of siomycin A on the expression of apoptosis-related molecules:
To investigate whether apoptosis-related molecules, downstream targets of FoxM1, were involved in siomycin Ainduced apoptosis, the expression of these was analyzed. As shown in Figure 4 , treatment with siomycin A markedly decreased the expression of anti-apoptotic proteins Bcl-2 and Mcl-1, as well as leading to caspase-3 cleavage. The results showed that siomycin A could influence the downstream events of FoxM1, which then led to cell apoptosis.
The oncogenic transcription factor FoxM1 is overexpressed in a majority of human carcinomas, while low expressed in normal cells, which is critical for proliferation, apoptosis, migration and invasion of cancer cells [16] . In particular, FoxM1 was reported to stimulate the proliferation of tumor cells during progression of NSCLC [5, 15] . These data showed that FoxM1 might be an attractive target for drug development for the treatment of lung cancer. Previous studies developed a cell-based screening system to identify small molecule inhibitors of FoxM1 activity. The results identified siomycin A as an inhibitor of FoxM1 transcriptional activity [14, 17] . In this study, the effect of siomycin A on FoxM1 expression was investigated in A549 cells, and consequently cell proliferation and apoptosis was also evaluated.
After treatment with siomycin A, the mRNA and protein levels of FoxM1 were markedly decreased in human lung adenocarcinoma A549 cells. As FoxM1 is important for the cell growth of cancer cells, then the effect of siomycin A on cell damage was further investigated. Our data suggested that siomycin A could inhibit the growth of A549 cells, and anti-proliferation was directly related to cell apoptosis induction. To gain insight into the molecular mechanism of siomycin A's action on cell damage, the involvement of FoxM1 target genes has been further evaluated in A549 cells. The Bcl-2 family is one of the major regulators of apoptosis, among which Bcl-2 and Mcl-1 were reported to be the downstream target genes of FoxM1 [18, 19] . correlation between FoxM1 suppression and caspase-3 cleavage [17, 20] . In the present study, treatment with siomycin A could lead to caspase-3 cleavage which might lead to FoxM1 suppression.
In summary, we demonstrated that FoxM1 suppression by siomycin A sensitized human lung adenocarcinoma A549 cells to cell apoptosis. Bcl-2 and Mcl-1 downregulation and caspase-3 cleavage resulting from FoxM1 suppression may explain the sensitivity of the cells to apoptosis following growth inhibition. Nevertheless, additional experiments are needed to determine if this compound can be an attractive candidate for further drug development.
Experimental

Chemicals and reagents: Siomycin A, a kind gift from Dr Yunying
Xie's laboratory, was dissolved in dimethyl sulfoxide (DMSO). Dulbecco's modified Eagle's medium (DMEM), penicillinstreptomycin, trypsin and fetal bovine serum (FBS) were obtained from Gibco (NY, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), PVDF membrane and enhanced chemiluminescence (ECL) detection kit from Beyotime (Nantong, China), Annexin V-FITC and PI double staining kit from PharMingen (CA, USA), and the antibodies against FoxM1, Bcl-2, Mcl-1, caspase-3, β-actin and HRP conjugated rabbit anti-mouse secondary antibody from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture: Human lung adenocarcinoma cell line A549 was obtained from the American Tissue Culture Collection. A549 cells were cultured in DMEM containing 10% FBS, antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin) and 2 mM glutamine, at 37°C in a humidified atmosphere comprising 95% air and 5% CO 2 . Culture medium was changed every 2 days.
Real time-PCR analysis:
Total cellular RNA was extracted from cultured cells using Trizol reagent (Invitrogen, CA, USA). qRT-PCR was performed using SYBR green PCR Master Mix (Takara, Shiga, Japan). The sequences of FoxM1 primer pair for realtime-PCR were as follows: 5'-TGCCCAGCAGTCTCTTACCT-3' (sense), 5'-CTACCCACCTTCTGGCAGTC-3' (antisense). Each amplification reaction underwent denaturation at 95°C for 30 s, amplification for 40 cycles at 95°C for 5 s, and annealing and extension at 60°C for 20 s using the ABI7500 sequence detection system (Life Technologies, ON, USA). β-Actin level was used for normalization.
Western blot analysis:
Cells were washed with ice-cold phosphate buffered saline (PBS) and lysed in 2% sodium dodecyl sulfate (SDS), 100 mM dithiothreitol (DTT), and 60 mM Tris, pH 6.8. Protein concentrations were quantified using the Bradford assay [21] . The samples (50 μg) were applied to 10% SDS polyacrylamide gel and transblotted onto a PVDF membrane. After blocking with 5% bovine serum albumin (BSA) in Tris-buffer saline with Tween 20 (TBST) for 1 h, membranes were incubated with the primary antibody overnight followed by secondary antibody incubation for 1 h at room temperature. Protein bands were visualized by an ECL detection kit. The density of each band was normalized by β-actin.
Cell growth assay:
The inhibition of cell growth was determined by MTT assay [22] . Cells (1×10 4 cells/well) were seeded in 96-well culture plates for 24 h. After incubation, cells were treated with various concentrations of siomycin A (0, 1, 2.5, 5, 10, 20 μM) for 24 h and 10 μL MTT stock solution (5 mg/mL) was added to each well for incubation for another 4 h at 37°C. Then the culture medium was removed and DMSO (100 μL) was added to dissolve the formazan crystals. Optical density (OD) was measured at 570 nm with an ELISA plate reader (Dynex, VA, USA). Cell viability was expressed as a percentage of the control.
Cell apoptosis assay:
Cell apoptosis was examined by flow cytometry (Becton-Dickinson, CA, USA) by double staining cells with Annexin V-FITC and PI. Cells (1×10 5 cells/well) were seeded in 6-well plates and treated with various concentrations of siomycin A (0, 2.5, 5, 10 μM) for 24 h. After treatment, cells were washed twice with ice-cold PBS and fixed in 75%, v/v, ethanol for 1 h at 4ºC. Then, cells were re-suspended in 300 μL binding buffer (Annexin V-FITC kit) containing 10 μL of Annexin V-FITC stock and 10 μL of PI. After incubation for 15 min at room temperature in the dark, the samples were then analyzed by CellQuest software (Becton-Dickinson, CA, USA) for the evaluation of cell apoptosis.
Statistical analysis:
Biostatistical analyses were conducted with the Prism 5.0 and SPSS 16.0 software package. Each experiment was made in triplicate and the results were indicative of 3 independent experiments. Results of multiple experiments were expressed as mean±SD. Differences between groups were examined for statistical significance using Student's t-test. A p value less than 0.05 was accepted as statistically significant.
